Roboearth – Lifestyle
Author:
Maze Therapeutics, Inc.
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 25, 2026
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026